Treat-to-target:​ mainstream or marketing?

wbldb

Cundy, T.¹

Treat-to-target: mainstream or marketing?

Osteoporos Int. October 2020;31(10):1835-1836

Cited Works (3)

Year	Entry
2014	McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang Y-C, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. NEJM. January 30, 2014;370(5):412-420.
2017	Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. NEJM. October 12, 2017;377(15):1417-1427.
2020	Thomas T, Casado E, Geusens P, Lems WF, Timoshanko J, Taylor D, Hofbauer LC. Is a treat-to-target strategy in osteoporosis applicable in clinical practice? consensus among a panel of European experts. Osteoporos Int. December 2020;31(12):2303-2311.